

# 89Zr

- <sup>89</sup>Zr-Desferrioxamine-anti-CD105 TRC105 chimeric monoclonal antibody
- <sup>89</sup>Zr-Desferrioxamine-anti-epithelial glycoprotein-1 hRS7 humanized monoclonal antibody
- <sup>89</sup>Zr-Desferrioxamine B-7E11 anti-prostate-specific membrane antigen monoclonal antibody
- <sup>89</sup>Zr-Desferrioxamine B-J591 anti-prostate-specific membrane antigen monoclonal antibody
- <sup>89</sup>Zr-Desferrioxamine B-Transferrin
- <sup>89</sup>Zr-Desferrioxamine *p*-isothiocyanatobenzyl-anti-EGFR nanobody 7D12
- <sup>89</sup>Zr-Desferrioxamine *p*-isothiocyanatobenzyl-anti-hepatocyte growth factor nanobody 1E2 fused to albumin-binding nanobody Alb8
- <sup>89</sup>Zr-Desferrioxamine *p*-isothiocyanatobenzyl-anti-hepatocyte growth factor receptor 1-armed antibody onartuzumab
- <sup>89</sup>Zr-Labeled fresolimumab (human anti-transforming growth factor-β monoclonal antibody)
- <sup>89</sup>Zr-Labeled *N*-succinyl-desferrioxamine-ranibizumab
- <sup>89</sup>Zr-Labeled *N*-suc-desferrioxamine-conjugated anti-carbonic anhydrase IX chimeric monoclonal antibody cG250-F(ab')<sub>2</sub> fragments
- <sup>89</sup>Zr-Labeled *p*-isothiocyanatobenzyl-desferrioxamine B (Df-Bz-NCS)-conjugated panitumumab, a fully human monoclonal antibody directed against the extracellular domain III of the epidermal growth factor receptor
- <sup>89</sup>Zr-Labeled trastuzumab, a humanized monoclonal antibody against epidermal growth factor receptor 2
- <sup>89</sup>Zr-*N*-Succinyl-desferal-anti-CD44v6 chimeric monoclonal antibody U36
- <sup>89</sup>Zr-*N*-Succinyl-desferal-chimeric monoclonal antibody G250
- <sup>89</sup>Zr-*N*-Succinyl-desferal-human anti-insulin-like growth factor 1 receptor monoclonal antibody R1507
- <sup>89</sup>Zr-*N*-Succinyl-desferrioxamine-bevacizumab
- <sup>89</sup>Zr-*N*-Succinyl-desferrioxamine-DN30

